These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38508940)

  • 1. Prostatic adenocarcinoma: molecular underpinnings and treatment-related options.
    Paralkar D; Akbari A; Aron M
    Urol Oncol; 2024 Jul; 42(7):203-210. PubMed ID: 38508940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.
    Wei L; Wang J; Lampert E; Schlanger S; DePriest AD; Hu Q; Gomez EC; Murakam M; Glenn ST; Conroy J; Morrison C; Azabdaftari G; Mohler JL; Liu S; Heemers HV
    Eur Urol; 2017 Feb; 71(2):183-192. PubMed ID: 27451135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity and microsatellite instability at chromosomal sites 1Q and 10Q in morphologically distinct regions of late stage prostate lesions.
    Latini JM; Rieger-Christ KM; Wang DS; Silverman ML; Libertino JA; Summerhayes IC
    J Urol; 2001 Nov; 166(5):1931-6. PubMed ID: 11586263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of genetic markers in the management of prostate cancer.
    Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
    Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic value of DNA alteration: loss of heterozygosity or allelic imbalance-promising for molecular staging of prostate cancers.
    Bryś M; Migdalska-Sęk M; Pastuszak-Lewandoska D; Forma E; Czarnecka K; Domańska D; Nawrot E; Wilkosz J; Różański W; Brzeziańska E
    Med Oncol; 2013 Mar; 30(1):391. PubMed ID: 23288724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA damage repair alterations are frequent in prostatic adenocarcinomas with focal pleomorphic giant-cell features.
    Lotan TL; Kaur HB; Alharbi AM; Pritchard CC; Epstein JI
    Histopathology; 2019 May; 74(6):836-843. PubMed ID: 30636012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microsatellite instability in adenocarcinoma of the prostate.
    Terrell RB; Wille AH; Cheville JC; Nystuen AM; Cohen MB; Sheffield VC
    Am J Pathol; 1995 Sep; 147(3):799-805. PubMed ID: 7677191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The landscape of somatic chromosomal copy number aberrations in GEM models of prostate carcinoma.
    Bianchi-Frias D; Hernandez SA; Coleman R; Wu H; Nelson PS
    Mol Cancer Res; 2015 Feb; 13(2):339-47. PubMed ID: 25298407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of the molecular genetics of human prostatic adenocarcinomas.
    Karan D; Lin MF; Johansson SL; Batra SK
    Int J Cancer; 2003 Jan; 103(3):285-93. PubMed ID: 12471610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-risk prostate cancer: a disease of genomic instability.
    Tapia-Laliena MA; Korzeniewski N; Hohenfellner M; Duensing S
    Urol Oncol; 2014 Nov; 32(8):1101-7. PubMed ID: 24931269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology of prostate cancer.
    Konishi N; Shimada K; Ishida E; Nakamura M
    Pathol Int; 2005 Sep; 55(9):531-9. PubMed ID: 16143027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New targets for therapy in prostate cancer: modulation of stromal-epithelial interactions.
    Chung LW; Hsieh CL; Law A; Sung SY; Gardner TA; Egawa M; Matsubara S; Zhau HE
    Urology; 2003 Nov; 62(5 Suppl 1):44-54. PubMed ID: 14607217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigenomic alterations in localized and advanced prostate cancer.
    Lin PC; Giannopoulou EG; Park K; Mosquera JM; Sboner A; Tewari AK; Garraway LA; Beltran H; Rubin MA; Elemento O
    Neoplasia; 2013 Apr; 15(4):373-83. PubMed ID: 23555183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
    Dobosy JR; Roberts JL; Fu VX; Jarrard DF
    J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer.
    Kumar-Sinha C; Chinnaiyan AM
    Urology; 2003 Dec; 62 Suppl 1():19-35. PubMed ID: 14747039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New prospectives of prostate cancer gene therapy: molecular targets and animal models.
    Hsieh CL; Chung LW
    Crit Rev Eukaryot Gene Expr; 2001; 11(1-3):77-120. PubMed ID: 11693967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of tissue markers as prognostic factors in prostatic adenocarcinoma.
    Hammond EH; Grignon DJ
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(2):419-22. PubMed ID: 7530701
    [No Abstract]   [Full Text] [Related]  

  • 20. Punctuated evolution of prostate cancer genomes.
    Baca SC; Prandi D; Lawrence MS; Mosquera JM; Romanel A; Drier Y; Park K; Kitabayashi N; MacDonald TY; Ghandi M; Van Allen E; Kryukov GV; Sboner A; Theurillat JP; Soong TD; Nickerson E; Auclair D; Tewari A; Beltran H; Onofrio RC; Boysen G; Guiducci C; Barbieri CE; Cibulskis K; Sivachenko A; Carter SL; Saksena G; Voet D; Ramos AH; Winckler W; Cipicchio M; Ardlie K; Kantoff PW; Berger MF; Gabriel SB; Golub TR; Meyerson M; Lander ES; Elemento O; Getz G; Demichelis F; Rubin MA; Garraway LA
    Cell; 2013 Apr; 153(3):666-77. PubMed ID: 23622249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.